Find Clinical Trials

Inclusion Criteria: * Aged over 18. * Ability to understand English * Ability to provide informed consent and attend in-person sessions * Chronic shoulder pain (pain lasting for at least 6 months) waiting on surgical pathway. * Comorbid mild-to-moderate anxiety or depression * Referred by a consultant orthopaedic surgeon. * Unresponsive to conventional treatment for 6 months including antidepressants, physiotherapy, and/ or oral analgesics * Mean NRS pain score ≥ 5 on most or all days either continuously or in motion Exclusion Criteria:● Inability to understand English and consent process * History of significant neurological or psychiatric conditions unrelated to chronic pain (e.g., epilepsy, psychosis, schizophrenia). * Skin lesions or piercing or extensive tattooing of the concha or Skin disease: infection, eczema or cancer of the ears or skin in region where VR headset or taVNS would sit * Presence of active implants (e.g. cochlear implant, implanted vagus nerve stimulator, cardiac pacemaker, implantable cardioverter defibrillator (ICD) deep brain stimulations or spinal cord stimulators, ventriculoperitoneal (VP) shunt). * Inability to tolerate VR (e.g., severe motion sickness, vertigo or balance issues, claustrophobia). * Fear of heights * Active infections, significant trauma, or other acute conditions affecting the shoulder. * Pregnancy and women trying actively to conceive * Pre-existing Persistent post-surgical pain-(\>6 months) from surgeries other than shoulder replacements * On- going alcohol and/ or drug problem * Widespread chronic pain conditions (fibromyalgia, complex regional pain syndrome) * Involvement in any clinical studies within the last 28 days prior to assessment * Other therapies such as other psychological interventions for A/D and pain in the shoulder are not allowed for the period of the study and follow up unless there is a psychiatric emergency. Participants may also not be involved in any trial on pain management or related to shoulders while participating in this VR/VNS trial.

Inclusion Criteria: * Adults of 18 years or above * English-speaking * A score of \<91 on Global Assessment of Functioning * Located in the Bahamas Exclusion Criteria: * ● Imminent suicide risk (assessed at screening using Columbia Suicide-Severity Rating Scale, see document titled " Screener updated 10-30- 24") * Severe mental disorder (e.g. psychotic disorders) * Severe cognitive impairment (e.g. severe intellectual disability or dementia)

Inclusion Criteria: * Written informed consent * Adults ≥18 years of age and ≤85 years of age * Patients planned for general anesthesia with an expected anesthetic time of at least 2 hours * Patients expected to receive postoperative opioid analgesia Exclusion Criteria: * Non-operative procedure (imaging) * Patients not admitted to the PACU postoperatively * Use of patient-controlled analgesia systems * Female patients who are pregnant or breastfeeding * Patients with asymmetric lung disease * American Society of Anesthesiologists (ASA) classification V * Emergency surgery (ASA E Modifier)

Inclusion Criteria: Meet DSM-5 criteria for major depressive episode confirmed by the Structured Clinical Interview for DSM-5 Disorders (SCID-5), with no prior manic or hypomanic episodes; diagnosed as major depressive disorder without psychotic features by two attending psychiatrists. First episode or recurrent, currently in a depressive episode (HAMD\_17≥17). Age 18 to 45 years, all sexes and genders. Han Chinese, right-handed. Junior high school education or above, no color blindness, able to understand and provide informed consent, and complete assessments and tests. Willing to participate voluntarily and sign written informed consent. Exclusion Criteria: Meet DSM-5 diagnostic criteria for any psychiatric disorder other than major depressive disorder. Received non-pharmacological treatments within the past 6 months, such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or systematic psychotherapy (≥ 10 sessions). Prior treatment with CCRT. Received antipsychotics or other medications affecting cognitive function within the past month, or cholinergic agents (e.g., donepezil, galantamine) within 14 days, memantine within 20 days, or other racetam drugs (e.g., piracetam) within 2 days prior to randomization. Organic brain disorders or severe physical illnesses (e.g., thyroid disease, lupus erythematosus, diabetes, liver/kidney/lung impairment, infection, major trauma). History of traumatic brain injury with loss of consciousness or other conditions that may interfere with this study. History of alcohol or substance abuse or dependence. Severe suicidal ideation or suicide attempt . Currently receiving hormonal therapy. Pregnancy, lactation, possibility of pregnancy, or planned pregnancy. History of epilepsy or family history of epilepsy. Implanted metal materials in the body (e.g., pacemaker, dental implants, metal intrauterine device). Any other factors that, in the investigator's opinion, place the participant at potential risk or interfere with the study participation.

Inclusion Criteria: 1. Male or Female patients aged ≥ 18 years and older who have signed an Informed Consent form. 2. All patients who attend the hVIVO respiratory site clinics who have a clinical diagnosis of asthma/any of the following: * Positive response to methacholine challenge test (AHR), or * Positive response to a bronchodilator responsiveness test, or * Peak Flow variability (i.e. highest - lowest PEF over the day/mean value of the two, × 100) \> 20%, or * Documented response (defined as ΔFEV1 ≥ 12% and ≥ 200 mL) after a cycle (e.g., 4 weeks) of regular maintenance anti-asthma treatment, or * physician diagnosis of current asthma. 3. In the PI/investigator(s) opinion, will be able to follow the study requirements. Exclusion Criteria: 1. Asthma patients who are not attending hVIVO respiratory site clinics. 2. Patients whose primary respiratory diagnosis (i.e. the condition causing most of their respiratory symptoms) is not asthma (however, a co-diagnosis of another respiratory disease such as COPD, bronchiectasis or interstitial lung disease together with asthma will be accepted) 3. Females who: 1. Are breastfeeding, or 2. Have a positive pregnancy test at any point during screening 4. Patients who, in the opinion of the physician, are unlikely to complete the 5 years of follow-up, e.g. poor literacy, substance abuse, life threatening comorbidities. 5. Contraindications for lung function testing, e.g., hemoptysis of unknown origin, history of pulmonary hypertension, previous pneumothorax, unstable cardiovascular status (severe heart failure, or ischemic heart disease), aneurysms (thoracic, abdominal or cerebral), recent eye surgery (e.g., cataract), recent thoracic or abdominal surgery. 6. Patients with lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction

Caregivers (CGs) Inclusion Criteria: * Aged 18 or above * Provide care to at least one homebound older adult (aged 60 or above) * Provide no less than 6 hours of caregiving per week * Able to communicate in either Cantonese, Mandarin or English * Willing to participate for the entire duration * Able to tolerate VR headset for at least 5 minutes (no severe motion sickness/epilepsy) Exclusion Criteria: * History of severe psychiatric disorders (e.g., schizophrenia, bipolar) * Severe cognitive impairment (MMSE \<10) * Major neurological diseases (e.g., recent stroke, severe Parkinson's) * Uncorrectable visual/hearing impairments affecting VR/video * Unable to tolerate VR due to motion sickness or discomfort * Care recipient receiving long-term care service that conflicts with study Care Recipients (CRs) Inclusion Criteria: * Aged 60 or above * Homebound (unable to leave home without assistance) * Stable medical condition * Willing to participate for the entire duration * Able to tolerate VR headset for at least 5 minutes (no VR contraindications) * Able to understand and provide informed consent Exclusion Criteria: Same as CGs, plus MMSE \<10

Inclusion Criteria: * Samples from patients with hereditary breast and ovarian cancer (HBOC), Lynch syndromes, and intestinal polyposis that will undergo genetic testing with commercial solutions provided by Sophia Genetics and sequenced on Illumina; * Samples from patients with rare and hereditary disorders that have been profiled with commercial solutions provided by Sophia Genetics and sequenced on Illumina; * Samples of patients for whom a report of the results is available; * Samples of patients who have previously consented and are aware if their genomic results. Exclusion Criteria: * patients for whom blood, DNA or tissue samples are not available for analysis; * samples that do not pass the quality check, set as DNA concentration, DNA integrity, library concentration and quality; * samples for which consent for future analysis has not be given.

Inclusion Criteria Internal Training and Validation Cohorts * BTC patients 1. Willing to voluntarily participate and able to comply with study procedures; if unable to read or sign, informed consent must be signed by a legally authorized representative (LAR). 2. Age 18-80 years (inclusive). 3. Able to provide required blood samples. 4. Pathologically confirmed biliary tract carcinoma (TNM stage I-IV). 5. Stable vital signs; ECOG performance status 0-1. 6. Adequate organ function: AST/ALT ≤ 5 × ULN; Child-Pugh class A or B; WBC \> 3 × 10⁹/L; ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L; Hemoglobin ≥ 90 g/L; Creatinine clearance ≥ 60 mL/min; Total bilirubin ≤ 3 × ULN. * Other gastrointestinal malignancies (to exclude BTC non-specific signals) 1. Voluntary participation with signed informed consent (or by LAR). 2. Age 18-80 years (inclusive). 3. Able to provide required blood samples. 4. Pathologically confirmed gastrointestinal malignancies other than BTC, including hepatocellular carcinoma, gastric cancer, colorectal cancer, and pancreatic cancer (TNM stage I-IV). 5. Stable vital signs; ECOG performance status 0-1. * Non-cancer participants (benign biliary disease) 1. Able to provide written informed consent. 2. Able to provide required blood samples. 3. Age 18-80 years (inclusive). 4. Pathologically or clinically diagnosed benign biliary diseases, including cholecystitis, cholelithiasis, choledocholithiasis, adenomyomatosis, gallbladder polyps, xanthogranulomatous cholecystitis, or primary sclerosing cholangitis. External Validation Cohorts * BTC patients 1. Voluntary participation with signed informed consent (or by LAR). 2. Imaging findings of malignant biliary stricture or mass, or serum CA19-9 \> 100 U/mL, highly suspicious for BTC, with planned surgery or biopsy for pathological confirmation. 3. Age 18-80 years (inclusive). 4. Able to provide required blood samples. 5. Stable vital signs; ECOG performance status 0-1. 6. Adequate organ function: AST/ALT ≤ 5 × ULN; Child-Pugh class A or B; WBC \> 3 × 10⁹/L; ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 75 × 10⁹/L; Hemoglobin ≥ 90 g/L; Creatinine clearance ≥ 60 mL/min; Total bilirubin ≤ 3 × ULN. * Healthy volunteers 1. Able to provide written informed consent. 2. Able to provide required blood samples. 3. Age 18-80 years (inclusive). Exclusion Criteria Training and Validation Cohorts * Cancer patients 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of curative cancer treatment within 3 years prior to blood collection. 5. Use of anti-tumor drugs within 30 days prior to blood collection. 6. Known bleeding disorders. 7. Known autoimmune diseases. 8. Concurrent other malignancies or multiple primary tumors. * Non-cancer participants 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of any malignant tumor. 5. Known bleeding disorders. 6. Known autoimmune diseases. 7. Clinically significant abnormalities on routine examination (excluding hepatitis, hepatic cysts, or benign pulmonary nodules). External Validation Cohorts * Cancer patients 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of or ongoing curative cancer treatment within 3 years prior to blood collection. 5. Use of anti-tumor drugs within 30 days prior to blood collection. 6. Known bleeding disorders or autoimmune diseases. 7. Concurrent other malignancies (including multiple primaries) or known cancer susceptibility gene carriers. 8. Pathology confirmed benign disease after biopsy/surgery. 9. Failure to confirm malignancy by pathology or imaging within 42 days after blood collection, or unclear lesion site/evidence. 10. Special exclusion criteria: * Pathology confirmed precancerous lesions. * Any local/regional or systemic anti-tumor therapy (including surgery, radiotherapy, targeted therapy, or immunotherapy) prior to blood collection. * Healthy volunteers 1. Pregnant or breastfeeding women. 2. History of organ transplantation or prior allogeneic bone marrow/stem cell transplantation. 3. Blood transfusion within 7 days prior to blood collection. 4. History of any malignant tumor. 5. Known bleeding disorders or autoimmune diseases. 6. Clinically significant abnormalities on health examination (excluding hepatitis, hepatic cysts, or benign pulmonary nodules).

Inclusion Criteria: 1. Age 12 to 18 years; 2. Scored 28 or higher on the children's depression rating scale-revised (CDRS-R); 3. Have the ability to read and write in Chinese; 4. Participant and at least one of their guardians provided written consent; 5. Have access to mobile phone and internet. Exclusion Criteria: 1. The researchers assessed that the adolescent's depressive symptoms were too severe to participate to CADS-D; 2. Scored 5 or higher on item 13 (suicidal ideation) on CDRS-R; 3. Participants who met diagnosis of other mental disorder except depression; 4. Severe physical illnesses or other physical disabilities that prevented the use of DCBT; 5. Within the past three months or currently undergoing any antidepressant treatment, including medication therapy, psychotherapy, and physical therapy; 6. Unavailability to follow up months after intervention.

Inclusion Criteria: * Pregnant patients ≥ 36 weeks gestation without major fetal anomalies * Age ≥ 18 years * Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital * At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF * 1 or more high risk factors: * History of preeclampsia * Type 1 or 2 diabetes * Multifetal gestation? * Renal disease * Autoimmune disease * 2 or more moderate risk factors: * Nulliparity * BMI \> 30 * First-degree relative with a history of preeclampsia * African American race * Low socioeconomic status * Age \> 35 years * History of low birthweight or small for gestational age * Previous adverse pregnancy outcome * Interpregnancy interval \> 10 years Exclusion Criteria: * Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines * Chronic hypertension, according to ACOG guidelines * Known allergy or contraindication to nifedipine * Inability or unwillingness to provide informed consent * Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)

Inclusion Criteria: * Is age 18 or older (male or female) * Have a documented diagnosis of CKD stage 3b, 4, or 5 and T2DM of 6 months or greater prior to screening. Patients may have treatment regimens associated with T2DM that include diabetic oral and/or injectable medications including insulin and/or GLP-1 receptor agonists. * In the opinion of the Investigator, has been on an appropriate, stable regimen for management of any complications present for the past six (6) months. * In the opinion of the Investigator, is able to do all of the following: * Provide valid informed consent. * Understand and comply with study procedures as presented in the consent process. * Has the capacity or support to attend all required visits. * If female, the subject must meet either of the following sets of conditions: o Is of non-childbearing potential, defined as meeting either of the following criteria: * Age ≥50 years and post-menopausal for at least one (1) year * Surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy * Is of childbearing potential and meets both of the following criteria: * Has a negative serum pregnancy test (beta-human chorionic gonadotropin) at screening. * Agrees to practice an acceptable method of birth control (contraception) from screening until at least 30 days after last study treatment Exclusion Criteria: * Has in the past two (2) years received treatment for a malignancy. * Current pregnancy or intends to become pregnant during the study * Has in the past one (1) year used non-prescription opioids or psychoactive drugs. * Has in the past six (6) months had a hypoglycemic event requiring urgent care and/or administration of glucagon, osteocalcin, or parenteral glucose, unless approved for enrollment by the Medical Monitor. * Has within the past one (1) month participated in a clinical study involving either of the following: * An investigational drug or procedure for any clinical indication * An investigation method for glucose control using approved agents * Is nursing or is planning to nurse during the study. * Has at screening a positive test for HIV (4th gen. screen), HBsAg, or HCV viral load. * Has at screening, one or more of the following abnormal lab results: * Hb \<8 g/dL * WBC \<2,000/µL * Platelets \<50,000/µL * ALT, AST, or Alkaline Phosphatase \>5x ULN * ALT or AST \>2.5x ULN, and Total Bilirubin \>2x ULN * Serum albumin \<3 g/dL * Has - in the opinion of the Investigator - psychiatric, behavioral, cognitive and/or clinical dysfunction (whether or not related to known medical illness or drug / alcohol use) that would affect the subject's safety and/or compliance. * Is on active dialysis at time of screening

Inclusion Criteria: Minimal eligibility criteria to be met for registration in the clinical trial: 1. TNBC: ER = 0%, PR = 0%, and HER2- (i.e., immunohistochemistry \[IHC\] with DAKO score ≤ 1 or fluorescence in situ hybridization \[FISH\]-negative) 2. or TNBC-like: ER ≤ 10% positive cells in IHC, PR \< 10% positive cells in IHC, and HER2- (i.e., IHC with DAKO score ≤ 1 or FISH negative) 3. All patients, independent from gender 4. ≥18 years at diagnosis 5. Histologically confirmed unilateral, primary invasive carcinoma of the breast Note: bilateral, multicentric, or multifocal carcinoma may be included, if there is a clear target (primary) lesion, that is subject to treatment decisions and solely evaluated and documented for study purposes. Histological confirmation of all lesions as TNBC is mandatory. 6. Clinical stage II-III at baseline 7. No clinical evidence for distant metastasis (M0) 8. Cognitive and language skills to complete quality of life (QoL) questionnaires Additional eligibility criteria to be met for assignment to cohort I or II: 9. Completed 9-12 weeks of NACT with CARBO + PEM or PAC q1w + PEM q3w with the last dose of NACT given less than 2 weeks ago. Patients may also be considered if their NACT treatment was switched to nab-PAC due to intolerance to PAC. * Patients with progressive disease during taxane-CARBO treatment are allowed to participate in cohort II after consultation with sponsor, provided that at least 6-9 weeks of NACT with taxane-CARBO q1w and PEM q3w have been administered * Patients experiencing toxicities due to PEM, in case of contraindications or other medical reasons against PEM administration (with or without permanent discontinuation of PEM) can nevertheless be included, even if PEM will not be administered anymore. The number of patients starting the study without PEM is limited to 10%. 10. Tumour block available for central pathology review 11. Performance Status ECOG ≤ 1 or Karnofsky Index ≥ 80% 12. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements 13. The patient must be capable of giving informed consent and be willing and able to comply with the requirements and restrictions in this protocol and accessible for treatment and follow-up 14. Laboratory requirements (female and male patients, ≤ 14 days old) * Neutrophils \> 1.5 109/L, * Platelets \> 100 109/L, * Total bilirubin \< 1 x upper level of normal (ULN), * ASAT (sGOT) \< 2.5 x ULN, * ALAT (sGPT) \< 2.5 x ULN, * Creatinine ≤1.5 × ULN OR clearance ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN 15. Clinical assessments: \- Normal Electrocardiogram (ECG) (within 42 days prior to induction treatment) 16. Negative pregnancy test (urine or serum) within ≤ 14 days prior to registration in premenopausal patients and immediate implementation of adequate contraceptive measures. Note: Pregnancy testing is to be repeated according to Schedule of Activities. 17. The following age-specific requirements apply: * Women aged \<50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site. * Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments. 18. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential and need to discontinue HRT to allow confirmation of post-menopausal status prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can participate without use of a contraceptive method. 19. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 1 (see Section 4.4.2), from the time of enrolment and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic, or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. 20. Female patients must not donate, or retrieve for their own use, ova from the time of randomization and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrolment in this study. 21. A male participant must agree to use a contraception as detailed in Appendix C of this protocol during the treatment period and for at least 7 months after the last dose of study treatment and refrain from donating sperm during this period. Exclusion Criteria: 1. Known hypersensitivity to the compounds or incorporated substances of the IMPs 2. Prior malignancy with a disease-free survival of \< 5 years, except curatively treated basalioma of the skin or pTis of the cervix uteri 3. Any history of invasive breast cancer 4. Previous or concurrent treatment with cytotoxic agents for any non-oncological reason unless clarified with sponsor 5. Concurrent treatment with other experimental drugs 6. Participation in another interventional clinical trial with or without any investigational, not marketed drug within 30 days or 5 half-lives of the respective drug, whichever is longer, prior to study entry. In case of other interventional trial contact Sponsor. 7. Concurrent pregnancy: patients of childbearing potential or potentially childbearing partners of male patients must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment 8. Breast feeding woman 9. Reasons indicating risk of poor compliance 10. Patients not able to consent 11. Known polyneuropathy ≥ grade 2 12. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including recovery from major surgery, autoimmune disease, known psychiatric/substance abuse disorders, acute cystitis, ischuria, and chronic kidney disease 13. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals 14. History of pneumonitis haemolytic anaemia, myocarditis, sclerosing cholangitis and exocrine pancreatic insufficiency, medical history of allogenic stem cell transplants, or solid organ transplant 15. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection. Patients should be tested for HIV prior to randomization if required by local regulations or ethics committee. Patients who test positive for HIV-antibody are excluded. 16. Active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with the following detectable viral loads will be excluded. 17. Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain

Inclusion Criteria: * \-- Adult aged 18 years or older; * Presenting with type 2 diabetes (under ALD), balanced or not, for 6 months or more; * Having been treated in the previous 6 months for periodontitis (stages 1 to 4 according to the new classification of periodontal and peri-implant diseases EFP-AAP 2018) in one of the participating centers and presenting a clinical situation allowing the transition to the periodontal follow-up phase (; (absence or limited number of sites presenting clinical signs of persistent periodontal inflammation) * Presenting more than 6 teeth; * Possessing a smartphone or tablet with internet access; * Affiliated to social security; * Patient able to read, write and understand French * Having signed a consent to participate in the study. Exclusion Criteria: * Patient presenting uncontrolled systemic diseases and diagnosed for less than 6 months or presenting a major aggravation of a systemic pathology according to the judgment of the investigator. * Pregnant or breastfeeding women; * Persons deprived of liberty by a judicial or administrative decision; * Adults subject to a legal protection measure (guardianship, curatorship).

Inclusion Criteria: * Inclusion criteria are accepting to undergo 18F-FAPI PET/MRI examinations and 1. diagnosed with local invasive breast cancer, 2. scheduled for neoadjuvant therapy as primary treatment, 3. has recurrent or new breast cancer, or 4. scheduled for neoadjuvant therapy as primary treatment with FDG-PET/CT applied for staging. Exclusion Criteria: * other primary malignancies than breast cancer, renal insufficiency or know allergy towards contrast agents, and MR incompatible implants.

Inclusion Criteria: * Age ≥18 years * Singleton pregnancy * Preeclampsia without severe features according to the ACOG definition * Antegrade diastolic flow in the umbilical artery Doppler * Gestational age between 36+0 and 38+6 weeks of gestation * Gestational age confirmed by fetal crown-rump length measurement in the first-trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates Exclusion Criteria: * Fetal death * Preeclampsia with severe features according to the ACOG definition, eclampsia, or any condition that requires immediate delivery * Absent or reversed end-diastolic flow in the umbilical artery Doppler * Non-reassuring CTG * Decreased fetal movements * Biophysical profile score ≤6 * Oligohydramnios * Refusal to provide informed consent * Fetal malformation * Placental abruption * Antiphospholipid antibody syndrome

Inclusion Criteria: * 18 years of age or older * Diagnosed with unilateral non-metastatic breast cancer * (to be) Treated with mastectomy and to be treated with adjuvant radiotherapy * Willing and able to provide written informed consent Exclusion Criteria: * History of DCIS or invasive breast cancer * Previous thoracic radiotherapy treatment * History of other malignancies (except for patients with basal or squamous cell skin cancer, in situ carcinoma of the cervix and patients who are disease-free at least 5 years following successful treatment for other malignancies)

Inclusion Criteria: * Voluntarily participate in the clinical trial, understand and sign the informed consent form, and agree to comply with the requirements specified in the protocol. * Age ≥ 18 years. * Female subjects must be postmenopausal and meet the trial requirements. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1. * Life expectancy ≥ 3 months. * Histologically or cytologically confirmed breast cancer. * Based on the most recent biopsy results of primary or metastatic tumor tissue, immunohistochemistry (IHC) confirms ER-positive status and HER-2-negative status. * At least one measurable target lesion according to RECIST v1.1. * Adequate bone marrow function within 2 weeks (14 days) prior to the initiation of study treatment, without the need for transfusion or growth factor (G-CSF, EPO, TPO, etc.) support. * Adequate liver function. * Renal function: serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (Ccr) \> 30 mL/min, with no significant electrolyte imbalances that are difficult to correct. * Coagulation function: International Normalized Ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. Exclusion Criteria: * Presence of symptomatic visceral disease or any other condition deemed unsuitable for endocrine therapy as per the investigator's judgment. * Presence of unresolved toxicities from prior therapy that have not recovered to ≤ CTCAE grade 1, excluding alopecia (any grade) or other toxicities considered by the investigator to pose no safety risk. * Received anti-tumor drug therapy within the specified time window prior to the first dose of the investigational drug. * Prior treatment with an experimental SERD or experimental ER antagonist. * Received radiotherapy within 4 weeks prior to the first dose of the investigational drug. * Used a strong CYP3A4 inhibitor within 7 days or 5 half-lives (whichever is longer) prior to the first dose. * Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has not recovered from significant side effects, or has significant traumatic injury, non-healing wounds, or fractures. * History of other active malignancies within 5 years prior to the first dose of the investigational drug. * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Inability to swallow the formulation, or gastrointestinal impairment/disease that may affect adequate absorption of the investigational drug. * Known clinically significant liver disease, including Child-Pugh class B or C, active viral hepatitis, or other hepatitis. * Current documented grade 1 or higher pneumonitis or interstitial lung disease. * Clinically significant pleural effusion, ascites, or pericardial effusion, defined as detectable on examination and requiring drainage within the past 2 weeks or additional medication to control symptoms. * Clinically significant uncontrolled cardiac disease and/or recent cardiac events. * History of bleeding tendency, thrombosis, or tumor embolism. * Planned treatment with everolimus and presence of uncontrolled diabetes despite adequate therapy. * Allergy to any of the investigational medicinal products or their components.

Inclusion Criteria: * To be diagnosed with spina bifida by a specialist. * Being between 18 and 75 years old. * Having their informed consent or the informed consent of their legal guardians. * Having Spanish as one of their main languages. * Having access to a computer (with a camera, microphone and speakers integrated) and Internet connection to take part in the videoconferences. Exclusion Criteria: * Age that is inconsistent with the established range. * The presence of any comorbid diagnosis or sensory deficit that would impede the effective execution of the intervention's activities.

Inclusion Criteria: * ≥18 years old and able to communicate in English * Fits into one of the following: 1. patients with GDM who are recently pregnant and/or postpartum; 2. health care providers (nurses, physicians, lactation consultants, etc.) who would implement the strategy 3. executive leadership Exclusion Criteria: * Subjects not meeting the inclusion criteria will be considered ineligible for participation

Inclusion Criteria: 1. Patients with HR+/HER2 negative MBC 2. On first- or second-line treatment 3. Life expectancy at least 12 months 4. Only females 5. Age 18 years or older 6. Able to read, write, and speak English 7. Willingness to follow protocol requirements 8. Have a smartphone with access to cellular service or computer access with internet service 9. Oriented to person, place, and time 10. Consume less than 3 servings of fruit and vegetable/day 11. Engage in less than 150 minutes moderate/vigorous intensity activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling) 12. Engage in a mind-body practice less than 4 times a month Exclusion Criteria: 1. Another primary cancer diagnosis within past 5 years (not including non-melanoma skin cancers) 2. Any major thought disorder (e.g., schizophrenia, dementia) 3. Communication barriers (e.g., hard of hearing) 4. Poorly-controlled or uncontrolled diabetes in the opinion of the physician(s) 5. Extreme mobility issues (e.g., unable to get in and out of a chair unassisted)